Command Palette

Search for a command to run...

Vivanza Biosciences Ltd.
2.08(+0.00%)
1W: +2.46%

Financials

Charts

YoY Net Sales
Operating Margin
EPS Growth

Pros & Cons

POSITIVES
  • Revenue increased to ₹7.62 crore in Q3 2023, showing growth from ₹6.56 crore in Q2 2023.
  • Operating profit margin improved to 2.74% in Q3 2023, up from 2.88% in Q2 2023.
  • Net profit of ₹0.26 crore in Q3 2023 indicates a positive turnaround from losses in earlier quarters.
NEGATIVES
  • Profit before tax decreased significantly to ₹0.26 crore in Q3 2023 from ₹0.21 crore in Q2 2023.
  • Expenses rose to ₹7.41 crore in Q3 2023, higher than Q2 2023's ₹6.37 crore, impacting profitability.
  • EPS remains low at ₹0.07 in Q3 2023, reflecting ongoing challenges in achieving consistent profitability.

Quarterly Results Data

FieldTrendSep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25
Revenue
7.626.564.422.4431.500.488.94
Expenses
7.416.374.662.182.991.471.528.87
Operating Profit
0.210.19-0.240.260.010.03-1.040.07
Other Income
0.050.02-0.03000.010.050.02
Interest
0.110.100.090.090.090.090.080.08
Depreciation
000.0100000
Profit Before Tax
0.260.21-0.270.270.010.04-0.990.09
Tax
000.150000.010
Net Profit
0.260.21-0.410.270.020.04-10.09
Eps in Rs
0.070.05-0.100.0700.01-0.250.02